Introduction
Caspase-8 activation plays an important role in the death receptor-mediated extrinsic apoptotic pathway in human cancer cells [1] . When binding to ligands, the death receptor is activated and forms the death induced signal complex (DISC) together with FADD and procaspase-8. Procaspase-8 is activated and initiates the caspase cascade which mediates cellular apoptosis. c-FLIP L is a major protein that can prevent caspase-8/10 activation in the DISC and inhibiting apoptosis mediated by death receptors. It has been found that c-FLIP L is upregulated in several carcinomas [2, 3] and overexpression of c-FLIP L can be responsible for chemoresistance and malignant transformation [4] [5] [6] . To date, more than 10 splicing variants of c-FLIP genes have been identified at the mRNA level. However, only c-FLIP L and c-FLIP S have been extensively studied at the protein level. Although these two splicing variants have distinct structural and functional properties, they have been found to be recruited to DISC and to inhibit caspase-8 activation. Recent studies have shown that c-FLIP L degradation is dependent on JNK-mediated E3-ligase Itch and AKT phosphorylation, while degradation of c-FLIP S seems to have different pattern [7, 8] .
Hsp90 is a pleiotropic molecular chaperone and functions as a key protein in the conformational maturation and stability of client proteins, many of which are kinases, cell cycle regulators and steroid receptors, etc. [9] . These client proteins play important roles in signaling transduction, cell proliferation and cancer chemoresistance. The Hsp90-based molecular chaperone complex interacts with its client proteins in an iterative way. Hsp90 cycles are driven by ATP-or ADP-bound conformations that are mediated via multiple rounds of ATP binding and hydrolysis [9] . Hsp90 inhibitors such as geldanamycin (GA) or its synthetic analogue 17-AAG, directly binds to the ATP-binding pocket in the N-terminal domain of Hsp90 and, hence, blocks the binding of nucleotides to Hsp90. Once Hsp90 activity is inhibited, the Hsp90-dependent protein dissociates from the multi-chaperone complexes and is targeted for degradation by the ubiquitin-proteasome system [10, 11] . 17-AAG-induced apoptosis has been previously reported to be associated with c-FLIP S down-regulation [12] . However, the relationship between Hsp90 and c-FLIP L has not been well elucidated.
C-terminus of Hsp70-interacting protein (CHIP) has the E3 ligase activity, and it binds to Hsp/Hsc70 and Hsp90 complex by means of its TPR (an amino-terminal tetratricopeptide) domain [13] . It has been reported that CHIP degrades Hsp90 client proteins, such as the glucocorticoid receptor, the cystic fibrosis transmembrane-conductance regulator and ErbB2 [13] [14] [15] . In this study, we show that CHIP is involved in c-FLIP L degradation induced by Hsp90 inhibition. Since both Hsp90 and c-FLIP L play a critical role in oncogenesis and chemoresistance, inhibition of Hsp90 by 17-AAG in combination with therapeutic agents targeting c-FLIP may be an efficacious strategy in patients with tumors that express high levels of c-FLIP L and other Hsp90 client proteins.
Results
Hsp90 inhibitor 17-AAG and GA induces c-FLIP L downregulation via ubiquitin-proteasome pathway in NSCLC cells 17-AAG-induced apoptosis has been previously reported to be associated with c-FLIP S down-regulation [12] . However the relationship between 17-AAG/GA and c-FLIP L has not been well elucidated. In this study we examined the effect of c-FLIP L expression induced by 17-AAG or GA in lung cancer cell lines including Calu-1, A549, H460 and H157. After treatment with 17-AAG and GA at the indicated concentrations for 48 h, c-FLIP L levels were reduced ( Figure 1A and B). We also performed time course experiments to monitor the expression of c-FLIP L . Calu-1 and H157 cells were treated with 17-AAG (1.0 μM) or GA(4.0 μM) for the indicated time. We found that the c-FLIP L expression decreased in a time-dependent manner. In Calu-1 and H157 cells, the time of c-FLIP L downregulation occurred as early as 4 h and was sustained for at least 48 h following 17-AAG or GA exposure ( Figure 1C) .
It has been reported that c-FLIP L degradation is correlated with ubiquitin [7] . To determine whether 17-AAG induces proteasome-mediated c-FLIP L degradation, we tested the effects of 17-AAG and GA on c-FLIP L expression in the absence or presence of the proteasome inhibitor MG132 in Calu-1 and H157 cells. As shown in Figure 2A and B, MG132 at the concentration of 20 μM abrogated the ability of 17-AAG and GA to reduce c-FLIP L , suggesting that 17-AAG-and GA-induced c-FLIP L down-regulation is dependent on proteasomemediated degradation pathway.
Inhibition of Hsp90 expression induces c-FLIP L downregulation
It has been documented that 17-AAG and GA induced degradation of Hsp90 client proteins [9] . Since we detected that c-FLIP L down-regulation was induced by 17-AAG and GA, we wondered whether c-FLIP L was a client protein of Hsp90. We knocked down Hsp90α/β with siRNA and then detected the c-FLIP L and Hsp90α/β protein levels by Western blot. Hsp90α/β protein levels were reduced after knockdown, and the c-FLIP L level was also decreased compared to the control ( Figure 3A and B), suggesting Hsp90 controls the stability of c-FLIP L protein. 
CHIP modulates the c-FLIP L degradation induced by 17-AAG
CHIP interacts with Hsp90 chaperone complexes and displays E3-ligase activity to degrade Hsp90 client proteins [13, 15] . In order to detect the interaction of CHIP with c-FLIP L , we explored dose experiments in Calu-1 and H157 cells. We found that c-FLIP L level was reduced while CHIP expression was slightly increased after treatment with 17-AAG ( Figure 4A and B). Furthermore, when CHIP was knocked down, the degradation of c-FLIP L was abrogated ( Figure 4C found that 17-AAG or GA induced activation of caspase-8, caspase-9, caspase-3 and cleavage of PARP in H157-LacZ control cells, as demonstrated by increased levels of cleaved bands ( Figure 5A ). This was not seen in the corresponding H157-c-FLIP L cells. We measured the survival of H157-LacZ to be 32.4% in cells treated with 2.0 μM 17-AAG for 48 h, whereas the survival of H157-c-FLIP L cells were more than 58.1% ( Figure 5B ) by SRB assay. The similar result was observed for SRB assay in GA-treated cells. From the above results, we conclude that ectopic overexpression of c-FLIP L protects cancer cells from apoptosis induced by Hsp90 inhibition.
17-AAG enhances celecoxib-induced c-FLIP L downregulation and apoptosis
We have reported that celecoxib (CCB) down-regulates c-FLIP L through ubiquitin-proteasome degradation [16] . To determine whether 17-AAG enhances celecoxibinduced c-FLIP L down-regulation and apoptosis, we investigated the level of c-FLIP L expression and caspase activation by combination treatment with CCB and 17-AAG in Calu-1 cells. We found that 17-AAG combination with CCB had synergistic effects on apoptosis induction by Western blotting and SRB assay ( Figure 6A and B) . c-FLIP L expression decreased further when 17-AAG was combined with CCB compared with the monotherapy Calu-1 cells. In addition, the activation of caspase-8, caspase-9, caspase-3 and the cleavage of PARP were more pronounced. This data suggests that 17-AAG may enhance chemotherapeutic agent-induced c-FLIP L down-regulation and apoptosis in lung cancer cells.
Discussion
Hsp90 plays a key role in conformational maturation and stability of client proteins in transducing proliferative and anti-apoptotic signals [10] . In the present study we found that Hsp90 inhibitor 17-AAG and GA or Hsp90 knockdown induced c-FLIP L down-regulation which subsequently resulted in cancer cell apoptosis. Although DR5 is an important death receptor in the extrinsic apoptotic pathway, in the above experiments, we failed to detect DR5 up-regulation (data no shown). This indicates that c-FLIP L may primarily contribute to Hsp90 inhibition-induced apoptosis in lung cancer cells.
Currently, more than one hundred client proteins of Hsp90 have been identified, and they are degraded when Hsp90 multi-chaperone complex activity is disrupted by the inhibitors. When we inhibited Hsp90 expression using siRNA technique and examined the c-FLIP L level, we found c-FLIP L was reduced in the cells whose Hsp90 was knocked down, suggesting that c-FLIP L is a client protein of Hsp90. It is reported when Hsp90 is inhibited, it recruits E3 ligase (e.g. CHIP) to degrade the client proteins [13] [14] [15] . When we knocked down CHIP, c-FLIP L degradation was inhibited after treatment with 17-AAG, which indicated that CHIP modulated c-FLIP L degradation in the NSCLC cell lines. Next, we performed immunoprecipitation experiments in Calu-1 cell lines. We found that CHIP was co-precipitated with c-FLIP L in the precipitated complex. We also found that Hsp90 was precipitated at the same time, hinting that c-FLIP L is the client protein of Hsp90 and CHIP modulates c-FLIP L degradation through the Hsp90 chaperone complex. Itch is reported as an E3 ligase of c-FLIP L in the mouse cells upon exposure to TNFα [7] . However, it has also been reported that some agents induced c-FLIP L degradation independently of Itch [17] [18] [19] . Additionally, we found that CHIP promotes the ubiquitination of c-FLIP, indicating CHIP regulates c-FLIP L degradation through uibiquitination when the cells were treated with 17-AAG.
It has been investigated that the clinically used antiinflammatory drug celecoxib induces c-FLIP L downregulation and facilitates cancer cell apoptosis alone or in combination with other agents [16] . We found that 17-AAG and celecoxib had synergistic effects in promoting c-FLIP L down-regulation and cellular apoptosis. In addition, overexpression of c-FLIP L could rescue cancer cells from apoptosis. These data suggest that c-FLIP L down-regulation plays important role in Hsp90 inhibition-induced apoptosis in NSCLC cells.
Conclusions
Our data reveals that c-FLIP L is down-regulated and apoptosis is induced effectively by Hsp90 inhibition, either by 17AAG and GA or siRNA technique, and c-FLIP L is degraded via proteasome-mediated pathway. CHIP modulates c-FLIP degradation induced by Hsp90 inhibition in human NSCLC cell lines. Targeting both c-FLIP L and Hsp90 may represent a promising therapeutic strategy for the patients whose tumors overexpress c-FLIP L and Hsp90 client proteins.
Materials and methods

Reagents and antibodies
17-AAG and GA were purchased from LC Laboratories (Pompano Beach). Celecoxib, MG132 and Anti-FLAG M2 Affinity Gel were purchased from Sigma (St. Louis, MO). Protein A and Protein G Agarose were purchased from Roche (Mannheim, Germany).
Mouse anti-caspase-3 and anti-caspase-8 monoclonal antibodies, rabbit anti-caspase-9 and anti-poly (ADP-ribose) polymerase (PARP) antibodies were purchased from Cell Signaling Technology (Danvers, MA). Mouse anti-FLIP L monoclonal antibody was purchased from Alexis Biochemicals (San Diego, CA). Mouse anti-Hsp90 antibodies were purchased from Abcam (Cambridge, UK). Mouse anti-Myc and anti-β-actin antibodies, rabbit anti-Flag and anti-CHIP antibodies were purchased from Sigma (St. Louis, MO).
Cell lines, cell culture and transfection
The human non-small cell lung cancer cell lines used in this study were obtained from the American Type Culture Collection (Manassas, VA) and were grown in RPMI 1640 supplemented with 5% fetal bovine serum at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. Cells were transfected with different plasmids by using the FuGene reagent from Roche (Indianapolis, IN), according to the manufacturer's instructions.
Cell survival assay
Cells were seeded in 96-well plate with an appropriate amount in 100 μL culture medium per well. On the second day, compounds or drugs were mixed in and the total volume of per well was 200 μL. Cells were treated for defined time and then cell viability was measured by sulforhodamine B (SRB) assay as described previously [20] .
Western blot analysis
The whole-cell protein lysates preparation and Western blot analysis were described in reference [21] .
Plasmids and establishment of stable cell lines that overexpress c-FLIP L
Plasmids of Myc-CHIP and Myc-CHIP (H260Q) were kindly provided by Dr. Hamid Band (University of Nebraska Medical Center, USA). Lenti-Flag-c-FLIP L was constructed before [22] . The cell clones that can overexpress c-FLIP L and LacZ were constructed as previously described [22] .
Knockdown of Hsp90, CHIP expression with siRNA siRNAs were synthesized by GenePharma (Shanghai, China). Control siRNA and Hsp90α/β siRNA target sequences were described before [23] . The target sequence of CHIP siRNA was 5 0 -AGGCCAAGCACGACAAGTA-3 0 . Transfection of siRNA was conducted as previously described [22] .
Immunoprecipitation
To precipitate Flag-tagged FLIP L or Myc-tagged CHIP proteins, cells were lysed with lysis buffer and Anti-FLAG M2 Affinity Gel beads or Myc antibody with Protein A/G Agarose beads (1:1 mix) were used to pull down Flag-tagged FLIP L or Myc-tagged CHIP proteins according to the manufacture's instructions.
